Development of AD214 a novel anti-fibrotic treatment for advanced Age related macular degeneration

老年性黄斑变性仍然是这个国家和其他工业化国家导致失明的主要原因。虽然这种疾病的晚期有治疗方法，但许多人在长期治疗后没有反应，或者失去了大量的视力。这项提案将为一种名为I-Body(AD214)的新疗法的商业化提供关键数据，该疗法通过减少注射的需要来阻止疤痕的形成，从而减少这种疾病的视力损失。

Age related macular degeneration remains the leading cause of blindness in this and other industrialised countries. Although treatment is available for an advanced form of the disease, many do not respond, or lose significant amounts of vision with long term treatment. This proposal will provide critical data for commericalizing a novel therapy called an i-body (AD214), that reduces vision loss in this disease by blocking the formation of scarring with reduced need for injections.